ACAD vs ALKS: fair value comparison
ACADIA Pharmaceuticals Inc. and Alkermes plc · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ACAD currently sits closer to the top of our discount ranking.
| ACAD | ALKS | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $25.61 | $49.53 |
| 12-month range | $21.24–$26.29 | $28.26–$51.72 |
| Sector rank | #111 of 113 Healthcare | #113 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | — | C |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | — | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ACAD fair value analysis · ALKS fair value analysis